RegASK: Unlocking Faster Market Access and Compliance Confidence with AI-Driven Regulatory Intelligence
Overview: How RegASK’s AI-Driven Regulatory Intelligence Platform Transforms Global Compliance RegASK is an AI-powered regulatory intelligence platform that automates regulatory research, compliance monitoring, and strategic regulatory guidance for pharmaceutical, medical device, and life sciences organisations navigating global regulatory requirements. It addresses a critical bottleneck in regulatory affairs operations: the time-intensive process of manually researching and […]
Feature Categories
Overview: How RegASK's AI-Driven Regulatory Intelligence Platform Transforms Global Compliance
RegASK is an AI-powered regulatory intelligence platform that automates regulatory research, compliance monitoring, and strategic regulatory guidance for pharmaceutical, medical device, and life sciences organisations navigating global regulatory requirements. It addresses a critical bottleneck in regulatory affairs operations: the time-intensive process of manually researching and interpreting complex regulatory requirements across multiple jurisdictions, tracking evolving health authority guidance, and maintaining current awareness of compliance obligations that traditionally requires extensive manual document review, expert consultation, and regulatory intelligence gathering that delays product development decisions and market entry planning.
The platform uses natural language processing, machine learning algorithms, and an extensive curated database of global regulatory information to provide instant answers to regulatory questions through an AI-powered search and query interface. By processing and structuring regulatory data from health authorities worldwide, RegASK enables regulatory professionals to ask complex compliance questions in natural language and receive immediate, reference-backed responses with direct citations to official guidance documents, regulations, and health authority publications. The system continuously updates its knowledge base to reflect regulatory changes and leverages machine learning to improve response accuracy based on user interactions and expert validation, enabling predictive insights into regulatory pathways and compliance requirements across different markets.
In practice, RegASK streamlines workflows for regulatory affairs teams by eliminating hours of manual regulatory research, providing instant access to verified regulatory intelligence, and enabling faster compliance decision-making through conversational AI interfaces that reduce dependency on scarce regulatory expertise. Organizations benefit from significantly reduced research time, improved consistency in regulatory interpretations across teams, and accelerated regulatory strategy development by replacing fragmented manual searches across multiple regulatory databases with a unified, AI-enabled intelligence platform. The system enables regulatory professionals to redirect time from routine research tasks toward higher-value strategic activities such as regulatory pathway optimisation, risk assessment, and cross-functional collaboration with clinical and commercial teams.
Last checked May 6, 2026: Platform remains active with major feature launches including AI-Assisted Label Review (Feb 2026) delivering instant compliance checks, enterprise governance controls (Apr 2026), and Veeva AI Partner Program integration (Apr 2026). Achieved ISO 27701 Privacy Certification (Jan 2026). Company published 2026 State of Regulatory Affairs & Compliance Report (Nov 2025) demonstrating market leadership and industry thought leadership.
What is RegASK?
RegASK is an agentic AI-powered regulatory intelligence platform that automates global regulatory monitoring, impact assessment, and compliance workflow orchestration for pharmaceutical, biotechnology, medical device, and life sciences organisations across 160+ countries. It is designed for regulatory affairs teams, compliance officers, quality professionals, and regulatory operations groups conducting multi-market regulatory research, submission planning, and ongoing compliance management. The platform differentiates itself through a multi-agent AI architecture using vertical large language models (LLMs) trained on regulatory ontologies, combined with a curated network of 1,700+ subject matter experts, to deliver triaged regulatory alerts, automated impact analysis against organisation-specific products and markets, conversational AI query capabilities (RegGenius), and end-to-end audit-ready workflow orchestration; organisations report up to 60% reduction in regulatory workload and 50% improvement in compliance workflow efficiency.
Why Do Leading Healthcare Teams Trust RegASK?
-
First regulatory intelligence platform in its category to achieve ISO/IEC 42001:2023 certification for AI Management Systems, demonstrating compliance with international standards for ethical AI governance in regulated industries.
-
Holds six independent security and privacy certifications, including SOC 2 Type II, ISO 27001 (Information Security), ISO 27018 (Cloud Privacy), ISO 27701 (Privacy Information Management), and GDPR compliance.
-
Strategic partnership with Veeva Systems announced in April 2026, integrating RegASK's agentic AI regulatory intelligence with Veeva RIM (Regulatory Information Management) for life sciences compliance workflows.
-
$10 million Series A funding raised in December 2022, led by Monograph Capital with participation from SPRIM Global Investments, providing enterprise stability and growth capital for platform development.
-
Powered by a network of over 1,800 subject matter experts across 160+ countries who validate and curate regulatory intelligence alongside AI automation.
-
Achieved 10x growth in platform adoption between 2024 and 2025, demonstrating market traction and enterprise validation in life sciences and consumer products sectors.
-
Strategic partnership with Esko announced in June 2025 to integrate AI-driven regulatory intelligence into packaging development workflows for regulated industries.
-
Year-long collaboration with CellCarta (global CRO laboratory services provider) documented reducing regulatory monitoring workload and modernising intelligence operations through automation.
-
Founder & CEO Caroline Shleifer and Chief Product & Technology Officer Amenallah Reghimi were recognised in Supply & Demand Chain Executive's 2026 Pros to Know awards for advancing agentic regulatory operations.
-
Platform designed with audit-ready workflow orchestration capabilities including full traceability, version control, and documentation trails to support regulatory submissions and compliance audits.
Top 3 Pain Points RegAsk Fixes in Healthcare
| Top Problems Solved by RegAsk | Description |
|---|---|
| 1. Regulatory Complexity & Compliance Risks | Automates monitoring and interpretation of evolving global regulations to minimize compliance risks and avoid costly delays. |
| 2. Manual, Time-Consuming Regulatory Research | Uses AI to extract and summarize relevant regulatory information quickly, reducing the time and effort needed for manual research. |
| 3. Fragmented Regulatory Intelligence & Data Silos | Centralizes regulatory data and insights in one platform, improving accessibility, collaboration, and informed decision-making. |
Feature Category Summary: RegASK
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | RegASK is positioned as an AI-driven regulatory intelligence and risk‑management platform that automates monitoring of global regulations, generates triaged alerts, and orchestrates end‑to‑end regulatory workflows, providing “audit‑ready insights in seconds” via its Action Hub command center and RegAlerts capabilities. Security and compliance FAQs state that RegASK is GDPR‑compliant, ISO 27001 and SOC 2 Type 2 certified, with encrypted data, RBAC, SSO, and extensive admin/data‑access logs with immutable audit trails, and for life‑science clients it “aligns with GxP and other relevant industry‑specific security frameworks where applicable,” which indicates support for regulated workflows and auditability even though formal FDA/EMA software validation is not explicitly documented. | YES |
| Clinical Trial Support | RegASK is framed as a regulatory‑intelligence and workflow platform for life‑science and CPG products, with use cases including regulatory strategy, submissions, risk assessment, and market‑access planning. RegGenius (the regulatory copilot) can answer questions such as “What are the clinical trial regulations in Europe?” and “What guidelines do I need to follow for quality control?” by searching curated, validated regulatory content, but there is no indication that the platform directly supports patient recruitment, protocol optimization, site selection, or clinical data monitoring; its role is regulatory guidance around trials rather than operational trial execution. “No public documentation found” for dedicated clinical‑trial design, recruitment, or monitoring modules. | NA |
| Supply Chain & Quality | Public materials describe RegASK as centralizing regulatory intelligence, mapping requirements to products and markets, and providing impact analysis and workflows for compliance actions across the product lifecycle in sectors including pharma, biotech, medical devices, food, and cosmetics. While regulatory content may encompass quality and GMP expectations, the platform is not described as a supply‑chain QA or manufacturing execution system, and there is no documentation of features like batch‑level QA tracking, serialization, or counterfeit detection; it focuses on regulatory text and compliance workflows, not operational quality‑control automation. “No public documentation found” for explicit supply‑chain or manufacturing‑quality functionality. | NA |
| Efficiency & Cost-Saving | RegASK cites a case where a UK‑based clinical research site achieved a 40% increase in operational efficiency and a 50% decrease in manual monitoring time by using the platform, reflecting automation of regulatory tracking and decision support. The RegGenius copilot and Action Hub command center automate alert creation, impact assessment, task triggering, and documentation generation using agentic AI and vertical LLMs, explicitly marketed as reducing manual research, eliminating external tracking spreadsheets, and transforming scattered compliance tasks into streamlined workflows with complete visibility and accountability. These are explicit claims of process automation, investigator/team time savings, and cost‑efficiency. | YES |
| Scalable / Enterprise-Grade | RegASK is described as an AI‑driven, end‑to‑end regulatory‑workflow platform used globally by life‑science and CPG organizations, enabling coverage in 150+ countries with a network of 1,700+ subject‑matter experts and rapidly growing platform adoption (10x growth noted alongside ISO 42001 certification). The security page details enterprise‑grade controls (Azure hosting, RBAC, SSO, scoped API keys, continuous monitoring, WAF, DDoS protection, pen‑testing, regional data hosting options, and audit artifacts available under NDA), indicating a SaaS architecture designed for large, multi‑market teams and enterprise deployments. | YES |
| HIPAA Compliant | RegASK’s security FAQs state the platform is GDPR‑compliant and certified to ISO 27001 and SOC 2 Type 2, with data encrypted in transit and at rest, role‑based access, and hosting on secure Microsoft Azure infrastructure, and external commentary notes frameworks including SOC 2, ISO 27001, HIPAA, and PCI DSS in the context of compliance best practices. However, the official FAQ and security pages do not clearly state that RegASK is formally “HIPAA compliant” or certified under HIPAA/HITECH, and no detailed HIPAA mapping is provided; any HIPAA mention appears in broader industry roundups rather than as an explicit vendor claim. “No public documentation found” with a definitive HIPAA‑compliance statement from RegASK itself. | NA |
| Clinically Validated | RegASK is positioned as a regulatory‑intelligence and compliance‑workflow platform, not a clinical diagnostic or therapeutic tool; documentation and case studies emphasize faster regulatory research, better compliance, and market‑access support, but do not describe prospective clinical trials, patient‑outcome studies, or regulatory device approvals validating RegASK as a clinical decision‑support or medical device product. “No public documentation found” for clinical validation in terms of therapeutic efficacy, patient outcomes, or medical‑device clearance. | NA |
| EHR Integration | RegASK’s product materials, Action Hub, and RegGenius descriptions focus on integrating curated regulatory content, organization‑specific documents (“bring your own content”), and business‑context metadata into one command center for compliance workflows. There is no mention of technical integration with EHR/EMR systems (e.g., HL7/FHIR connectors) or embedding into clinical workflows; the platform operates in the regulatory and compliance domain, not within clinical information systems. “No public documentation found” for EHR integration. | NO |
| Explainable AI | RegASK emphasizes “agentic AI” and vertical LLMs that operate on curated, validated regulatory data with business‑context metadata, and the RegGenius copilot answers questions by drawing from an organization’s approved regulatory content and scoped context, which gives users a clear view of the data sources and scope used for answers. External analyses describe RegASK’s AI as delivering explainable decision‑making for regulatory insights, and the platform’s impact‑analysis and context‑engineering features show how each alert is contextualized to specific products and markets, which amounts to transparent, traceable AI‑driven recommendations rather than opaque black‑box outputs. | YES |
| Real-Time Analytics | RegASK markets “real-time regulatory updates, alerts, and analytics dashboards” for proactive compliance monitoring, with RegAlerts enabling organizations to track regulation changes in their scope and receive customized alerts, summarized updates, and impact analyses. The Businesswire and product pages describe “near real‑time” RegGenius processing, where uploaded documents become immediately available for AI analysis, as well as continuous monitoring of global regulatory sources, demonstrating real‑time or near real‑time analytics over regulatory data streams rather than batch‑only updates. | YES |
| Bias Detection | Although RegASK uses AI and ML for regulatory text analysis and emphasizes accuracy, contextualization, and risk identification, no documentation describes features specifically aimed at algorithmic bias detection, fairness metrics, or performance analysis across demographic or clinical sub‑cohorts. The domain is regulatory content rather than patient‑level data, and bias‑detection tooling is not mentioned. “No public documentation found” for bias‑detection capabilities. | NA |
| Ethical Safeguards | RegASK maintains an “Enterprise‑Grade Security & Compliance” framework with GDPR compliance, ISO 27001 and SOC 2 Type 2 certification, encryption, RBAC/SSO, comprehensive admin and data‑access logs, and a documented incident‑response plan; the security page also notes that model usage is monitored, restricted to approved providers with documented risk assessments, and includes human‑in‑the‑loop controls as part of its Artificial Intelligence Management System (AIMS), which is certified to ISO/IEC 42001:2023 for AI governance. These elements provide explicit AI‑governance safeguards (risk‑assessed models, human‑in‑the‑loop oversight, logging, and responsible‑AI certification), although there is less detail on per‑use‑case restriction tooling or explicit consent‑management for source data; overall, there is sufficient evidence of built‑in AI governance controls and ethical‑AI management. | YES |
Risks & Limitations: RegASK
-
Predictive performance depends on dataset quality, completeness, and consistency; missing or inaccurate regulatory data can reduce reliability.
-
Outputs are decision-support only; regulatory teams must validate recommendations before submission or compliance action.
-
Integration with proprietary regulatory tracking systems, eCTD platforms, or enterprise workflows may require IT effort and configuration.
-
Regulatory or compliance review is necessary when using AI outputs to inform submissions, audits, or regulatory decision-making.
-
Model updates must be monitored for changing regulatory guidelines or country-specific requirements to maintain accuracy.
-
Limited explainability for complex regulatory predictions may require human interpretation and documentation to satisfy internal and external audits.
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
